The recent XVII International AIDS Conference (AIDS 2008) was dotted with only a few truly noteworthy research presentations but this was one of the big ones: Results from a major U.S. study found that people who start HIV treatment with a viral load above 100,000 are less likely to control that viral load if they take a Ziagen (abacavir)-based regimen than a Viread (tenofovir)-based regimen. http://www.thebodypro.com/content/confs/aids2008/art47882.html?mtrk=9774874